Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $184.55 million. The enterprise value is $240.59 million.
Important Dates
The last earnings date was Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 9.86 million shares outstanding. The number of shares has increased by 16.71% in one year.
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +16.71% |
| Shares Change (QoQ) | +7.53% |
| Owned by Insiders (%) | 39.70% |
| Owned by Institutions (%) | 17.69% |
| Float | 5.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.09 |
| Forward PS | 1.71 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.86
| Current Ratio | 1.86 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.60 |
Financial Efficiency
Return on equity (ROE) is -383.09% and return on invested capital (ROIC) is -22.33%.
| Return on Equity (ROE) | -383.09% |
| Return on Assets (ROA) | -18.79% |
| Return on Invested Capital (ROIC) | -22.33% |
| Return on Capital Employed (ROCE) | -39.64% |
| Weighted Average Cost of Capital (WACC) | 7.61% |
| Revenue Per Employee | $264,967 |
| Profits Per Employee | -$105,584 |
| Employee Count | 334 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 14.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.56% in the last 52 weeks. The beta is 0.57, so Biodesix's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +8.56% |
| 50-Day Moving Average | 10.87 |
| 200-Day Moving Average | 8.18 |
| Relative Strength Index (RSI) | 76.97 |
| Average Volume (20 Days) | 167,478 |
Short Selling Information
The latest short interest is 239,064, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 239,064 |
| Short Previous Month | 249,443 |
| Short % of Shares Out | 2.42% |
| Short % of Float | 4.47% |
| Short Ratio (days to cover) | 0.57 |
Income Statement
In the last 12 months, Biodesix had revenue of $88.50 million and -$35.27 million in losses. Loss per share was -$4.67.
| Revenue | 88.50M |
| Gross Profit | 71.78M |
| Operating Income | -27.77M |
| Pretax Income | -35.27M |
| Net Income | -35.27M |
| EBITDA | -22.10M |
| EBIT | -27.77M |
| Loss Per Share | -$4.67 |
Full Income StatementBalance Sheet
The company has $18.99 million in cash and $75.03 million in debt, with a net cash position of -$56.04 million or -$5.68 per share.
| Cash & Cash Equivalents | 18.99M |
| Total Debt | 75.03M |
| Net Cash | -56.04M |
| Net Cash Per Share | -$5.68 |
| Equity (Book Value) | -2.47M |
| Book Value Per Share | -0.30 |
| Working Capital | 15.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.27 million and capital expenditures -$259,000, giving a free cash flow of -$23.53 million.
| Operating Cash Flow | -23.27M |
| Capital Expenditures | -259,000 |
| Free Cash Flow | -23.53M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
Gross margin is 81.11%, with operating and profit margins of -31.37% and -39.85%.
| Gross Margin | 81.11% |
| Operating Margin | -31.37% |
| Pretax Margin | -39.85% |
| Profit Margin | -39.85% |
| EBITDA Margin | -24.97% |
| EBIT Margin | -31.37% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.71% |
| Shareholder Yield | -16.71% |
| Earnings Yield | -19.11% |
| FCF Yield | -12.75% |
Analyst Forecast
The average price target for Biodesix is $32.50, which is 73.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.50 |
| Price Target Difference | 73.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biodesix has an Altman Z-Score of -7.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.28 |
| Piotroski F-Score | 3 |
